Core Insights - BioMarin Pharmaceutical is focusing on disciplined expense management and efficient cost allocations to achieve leveraged growth, expecting earnings per share growth at roughly three times revenue growth in 2025 [1] - The company anticipates "high single digits" growth for both Skeletal Conditions and Enzyme Therapies, with the planned Amicus acquisition expected to add two high-growth products [2][7] - BioMarin reported a total revenue growth of 13% in 2025, with Skeletal Conditions growing by 26% and Enzyme Therapies by 9% [3] Financial Performance - BioMarin's revenue growth in 2025 was driven by a strong performance in its Skeletal Conditions unit, which includes the product VOXZOGO [3] - The company expects continued operating margin expansion and cash flow growth alongside revenue growth [1] Strategic Initiatives - The company is executing a three-pillar strategy focused on growth, innovation, and value commitment, which includes recent revenue momentum and multiple clinical milestones [4] - The planned acquisition of Amicus is seen as a strategic move to enhance product offerings in rare genetic conditions, with expectations of slight dilution in 2026 but substantial accretion thereafter [7][14] Product Pipeline and Development - BioMarin is advancing its pipeline with key programs such as BMN 351 for Duchenne muscular dystrophy and BMN 401 for ENPP1 deficiency, with significant data expected in the near term [5][16] - The company is also developing a long-acting version of VOXZOGO, BMN 333, aimed at being superior to existing therapies [10] Market Dynamics - VOXZOGO revenue is expected to be weighted towards the second half of the year, with approximately 75% of its revenue coming from outside the U.S. [17] - The company is focusing on expanding its geographic reach and improving diagnosis rates for conditions like Fabry disease through the Amicus acquisition [13]

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Brian (CFO), Cristin (Chief Commercial Officer) Key Highlights of 2025 - **Revenue Growth**: Total revenue grew by 13% in 2025, with Voxzogo revenue increasing by 26% and enzyme therapies by 9% [2][3] - **Profitability Improvement**: Earnings per share growth outpaced revenue growth, achieving over 2 times leverage on the bottom line after adjusting for special items [3] - **Amicus Acquisition**: Announcement of the acquisition of Amicus, expected to close in Q2 2026, which will add two high-growth rare disease assets to BioMarin's portfolio [3][4] 2026 Outlook - **Revenue Guidance**: Expected revenue growth in both enzyme therapies and skeletal conditions at 7%-8%, with a total revenue headwind of about 3% due to decreasing royalty and other revenues [4] - **Voxzogo Revenue Guidance**: Projected revenue for Voxzogo in 2026 is between $975 million and $1.025 billion, influenced by international market access negotiations and competitive impacts [14][15] - **Pipeline Advancements**: Anticipated phase 3 readouts for hypochondroplasia and BMN 401, with potential for significant market impact [5][47] Competitive Landscape - **Voxzogo Competition**: Voxzogo faces competition, but only 25% of its revenues are from the U.S., which is subject to competition, representing about 7% of total revenue [8][15] - **Market Positioning**: BioMarin is confident in Voxzogo's established position in the achondroplasia community, emphasizing the complexity of switching treatments for patients [7][8] Clinical Pipeline - **Hypochondroplasia**: Estimated total addressable patient population of 14,000, with a focus on increasing disease awareness and shortening diagnosis times [24][25] - **BMN 351**: A second-generation exon skipping therapy for Duchenne muscular dystrophy, showing promising early data with a target of 10% dystrophin expression [6] - **ENPP1 Deficiency**: Anticipated phase 3 data readout for BMN 401, with an estimated addressable patient population of 2,000-2,500 globally [47][48] Amicus Acquisition Impact - **Revenue Contribution**: Amicus products generated over $600 million in 2025, expected to enhance BioMarin's revenue portfolio significantly [18] - **Operational Synergies**: Anticipated operational expense synergies from integrating Amicus, with a focus on leveraging existing global capabilities [30][32] Financial Strategy - **Deleveraging Plan**: Target to reduce debt to less than 2.5 times within two years post-acquisition, with a focus on maintaining operational profitability [56][57] - **Future Business Development**: Continued interest in pipeline clinical stage transactions to enhance long-term revenue growth [58] Additional Insights - **Palynziq Expansion**: Recent label expansion for Palynziq to include adolescents, with an estimated 1,500 eligible patients in the U.S. [39][41] - **Seasonality in Revenue**: Historical trends indicate a ramp-up in revenue towards Q4, with a typical step down in Q1 due to international order timing [49][50] This summary encapsulates the key points discussed during the BioMarin Pharmaceutical FY Conference, highlighting the company's growth trajectory, competitive positioning, and strategic initiatives for the upcoming year.

BioMarin Pharmaceutical Conference Call Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date**: March 09, 2026 - **Key Speakers**: Brian Mueller (CFO), Cristin Hubbard (CCO) Key Points Industry and Company Performance - BioMarin reported a **13% revenue growth** in 2025, with the Skeletal Conditions unit (including VOXZOGO) growing by **26%** and Enzyme Therapies by **9%** [4][5] - The company anticipates **high single-digit growth** for both Skeletal Conditions and Enzyme Therapies in 2026 [4] Strategic Growth Pillars - BioMarin's corporate strategy is built on three pillars: **growth, innovation, and value commitment** [4] - The company is preparing for the **Amicus acquisition** in Q2 2026, which is expected to enhance its portfolio with two high-growth products in rare genetic conditions [5] Product Pipeline and Innovations - Recent approval of **PALYNZIQ** for adolescents and upcoming **Phase 3 data readouts** for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency [5][6] - Ongoing development of **BMN 351** for Duchenne muscular dystrophy and **BMN 333**, a long-acting CNP for achondroplasia [6] Market Dynamics and Patient Retention - BioMarin is focused on patient retention for VOXZOGO, emphasizing that **efficacy and safety** are key factors influencing caregivers' decisions to switch therapies [10][11] - Approximately **two-thirds** of KOLs and caregivers believe that switching therapies is unlikely if patients are doing well on current treatments [11] Achondroplasia Market Insights - The company is working to build a broader health narrative around achondroplasia beyond just growth, focusing on overall health benefits [12][14] - BioMarin has a long history with VOXZOGO, having started its development program over **15 years ago**, and is now filing for full approval based on long-term data [20] Hypochondroplasia Opportunity - The Phase 3 trial for hypochondroplasia is expected to yield data in the **first half of 2026**, with strong enrollment indicating market excitement [25][26] - The company is focusing on **disease awareness** and improving the diagnosis journey for hypochondroplasia patients [28][30] Amicus Acquisition and Market Expansion - The acquisition of Amicus is expected to enhance BioMarin's market presence, with **Galafold** currently available in **40 countries** and BioMarin operating in **80** [38] - The integration of Amicus products is anticipated to unlock additional value through deeper market penetration and improved diagnosis efforts [39][43] Financial Projections - The Amicus acquisition may be slightly dilutive in **2026** but is expected to be accretive in the first 12 months and substantially accretive thereafter [45] - BioMarin expects **VOXZOGO revenues** in the second half of 2026 to exceed the first half, primarily due to international order timing [64][66] Manufacturing and Operational Strategy - BioMarin is recognized for its high-quality manufacturing capabilities and plans to leverage these skills for Amicus products, particularly POMP [51][53] Clinical Data and Future Expectations - Upcoming data cuts for **BMN 351** and pivotal Phase 3 data for **ENPP1 deficiency** are anticipated, with a focus on patient diagnosis and treatment initiation [54][57] Conclusion BioMarin Pharmaceutical is positioned for continued growth through strategic acquisitions, a robust product pipeline, and a commitment to enhancing patient care in rare genetic conditions. The company is focused on leveraging its manufacturing expertise and expanding its market presence while maintaining a strong emphasis on patient retention and treatment efficacy.

Core Insights - BioMarin Pharmaceutical (BMRN) reported fourth-quarter 2025 adjusted earnings per share of 46 cents, exceeding the Zacks Consensus Estimate of 25 cents, but reflecting a 50% decline year over year due to a $119.2 million inventory write-off from the withdrawal of Roctavian from the market [1][7] - Total revenues for the fourth quarter reached $875 million, a 17% increase year over year, driven by strong sales of Voxzogo, surpassing the Zacks Consensus Estimate of $830 million [2][7] - Despite the positive revenue growth, BioMarin's shares fell 2.6% in after-hours trading, likely influenced by the decision to withdraw Roctavian [2] Financial Performance - Net product revenues were approximately $859.3 million, up 17% year over year, primarily due to increased sales from Voxzogo and other enzyme therapies [4][8] - Voxzogo sales reached $273 million, a 31% increase year over year, attributed to new patient initiations and large government orders, particularly in Latin America [4][7] - Royalty and other revenues increased by 30% year over year to over $15.2 million [5] Product Performance - Sales from enzyme therapies rose 13% year over year to $549 million, driven by higher patient demand and favorable order timing [8] - Specific product sales included Palynziq at $125 million (up 25%), Vimizim at $206 million (up 8%), Naglazyme at $120 million (up 9%), and Aldurazyme at $49 million (up 26%) [9] Strategic Decisions - BioMarin announced the voluntary withdrawal of Roctavian after failing to find a buyer, resulting in a $119.2 million charge in Q4 [1][11] - The company has restructured its organizational framework, consolidating revenues from five products under the "Enzyme Therapies" segment [8] Full-Year Results and Future Outlook - For the full year 2025, BioMarin reported total revenues of $3.22 billion, a 13% increase year over year, with earnings per share of $3.15, down 11% from the previous year [13] - For 2026, BioMarin anticipates total revenues between $3.33 billion and $3.43 billion, with a Zacks Consensus Estimate of around $3.35 billion [14] - The company expects Voxzogo sales to contribute significantly, projected between $975 million and $1.03 billion, and enzyme therapies revenues between $2.23 billion and $2.28 billion [17] Pipeline Developments - The FDA has accepted BioMarin's supplemental biologics license application for Palynziq, with a decision expected by February 28, 2026 [20] - BioMarin is advancing its CANOPY clinical program for Voxzogo, with data expected in the first half of 2026 [21] - The company plans to initiate a phase II/III study for BMN 333, a long-acting formulation for growth-related conditions, in the first half of 2026 [23]

Financial Data and Key Metrics Changes - Total revenues for 2025 grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [6][11] - Fourth quarter revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [11][12] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [14][15] Business Line Data and Key Metrics Changes - Enzyme therapies revenue increased by 9% year-over-year for 2025, with Palynziq growing by 22% and Vimizim by 7% [13][21] - Voxzogo revenue for 2025 totaled $927 million, with 73% generated outside the United States, highlighting the company's global reach [12][13] - Palynziq is expected to remain a primary growth driver in 2026, supported by an anticipated adolescent label expansion [22] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated globally by year-end [23] - The company is focusing on expanding its market presence in newly launched countries and increasing penetration in existing markets, particularly among children under two years of age [24][27] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, emphasizing the importance of international markets [26] Company Strategy and Development Direction - The company plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [7][8] - BioMarin aims to build on Voxzogo's leadership in achondroplasia and expand its indications to include hypochondroplasia [9] - The company is actively engaged in business development targeting pipeline assets to drive long-term growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain revenue growth and profitability, with expectations for high single-digit growth in enzyme therapies and Voxzogo in 2026 [17][19] - The company anticipates total revenues for 2026 to be in the range of $3.325 billion to $3.425 billion, excluding contributions from the Amicus acquisition [18] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [39][40] Other Important Information - The company recorded approximately $240 million in special items during Q4 due to the strategic decision to withdraw Roctavian from the market [14] - BioMarin secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business outlook [15][16] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [36][37] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [51] Question: Expected timing for data readouts from the phase II CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [78] Question: Voxzogo guidance and market access considerations - Management is being cautious regarding routine market access negotiations, which may impact revenue growth but also present opportunities for broader access [81]

Financial Data and Key Metrics Changes - In 2025, total revenues grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [4][10] - For Q4 2025, total revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [10][11] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [12][13] Business Line Data and Key Metrics Changes - Enzyme therapies revenue for 2025 increased by 9% year-over-year, led by 22% growth for Palynziq and 7% growth for Vimizim [11][12] - Voxzogo revenue for 2025 totaled $927 million, with approximately 73% generated outside the United States, highlighting BioMarin's global reach [11][12] - Palynziq is expected to remain the primary growth driver in the enzyme therapy portfolio, supported by an anticipated adolescent label expansion [20] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated worldwide by the end of the year [21] - The company anticipates continued high patient demand across both enzyme therapies and Voxzogo in 2026, resulting in high single-digit growth rates [15][16] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, indicating a strong international market presence [23] Company Strategy and Development Direction - BioMarin plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [5][6] - The company is focused on pipeline expansion and innovation, with several anticipated data readouts and regulatory activities planned for 2026 [26][29] - BioMarin aims to solidify its revenue growth potential and transform its cost structure to achieve a strong operating margin profile [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding Voxzogo's market presence and achieving blockbuster status [9][10] - The company anticipates that integrating Amicus's products will significantly enhance its 2026 outlook and accelerate revenue growth through the 2030s [9][16] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [38][46] Other Important Information - BioMarin made a strategic decision to withdraw Roctavian from the market, resulting in approximately $240 million in special items recorded during Q4 [12] - The company secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business and financial outlook [13][14] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [33][34] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [46][47] Question: Expected timing for data readouts from the phase 2 CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [74] Question: Voxzogo guidance and market access negotiations - Management is being cautious regarding routine market access negotiations, which may impact pricing but also provide opportunities for broader patient access [77][78]

Group 1 - Amicus Therapeutics Inc. (NASDAQ:FOLD) is identified as one of the 13 stocks with high upside potential, with a price target maintained at $14.50 by TD Cowen analyst Ritu Baral [1][2] - The company's fourth-quarter and full-year 2025 total product revenue slightly exceeded expectations, driven by strong performance of the Fabry disease medication Galafold, while Pompe disease medication revenues aligned with broader Wall Street expectations [1] - The strategic landscape for Amicus is shaped by BioMarin's agreement to acquire the company for $14.50 per share, with the deal expected to close by Q2 2026, pending shareholder and regulatory approvals [2] Group 2 - Amicus Therapeutics focuses on discovering, developing, and delivering medicines for individuals with metabolic diseases [3] - Despite the potential of Amicus as an investment, certain AI stocks are considered to offer greater upside potential with less downside risk [4]

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - Investors are expected to focus on Amicus Therapeutics' sales performance and updates regarding its merger with BioMarin Pharmaceutical during the upcoming earnings report for Q4 and full-year 2025 [1][6]. Sales Performance - The Zacks Consensus Estimate for Q4 sales is $179.9 million, with earnings expected at 13 cents per share [1]. - Galafold sales are projected to be a key revenue driver, with estimates for Q4 sales at $157 million, reflecting strong demand and compliance [8]. - The combination therapy Pombiliti + Opfolda is also expected to contribute positively to revenues, following its FDA approval in September 2023 [7][8]. Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS is stable at 35 cents, while the estimate for 2026 is 65 cents [2]. - The earnings surprise history shows Amicus has beaten earnings expectations only once in the last four quarters, with an average negative surprise of 20.21% [4]. Merger Details - BioMarin has agreed to acquire Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [9][10]. - Post-acquisition, BioMarin will add Galafold and Pombiliti to its portfolio and gain exclusive U.S. rights to the late-stage drug DMX-200 [10]. Stock Performance - Amicus shares have increased by 104.9% over the past six months, outperforming the industry growth of 23.8% [11]. - The stock is currently trading at a price-to-sales (P/S) ratio of 7.42, which is higher than the industry average of 2.46, but below its five-year mean of 8.72 [14][15]. Investment Outlook - The acquisition by BioMarin is seen as a potential catalyst for value realization beyond organic sales growth, with optimism surrounding the strong sales of marketed products [16]. - Despite concerns regarding competition and reliance on Galafold, the company is expected to maintain growth potential, making it advisable for current investors to hold their positions [17][19].

Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as one of the best biotech stocks under $20, primarily due to its innovative treatments for rare diseases [1] - Jefferies downgraded FOLD from Hold to Buy and reduced the price target from $16 to $14.50, reflecting a cautious outlook despite takeover interest [1][2] - BioMarin announced plans to acquire Amicus Therapeutics for $14.50 per share, valuing the company at approximately $4.8 billion, which includes two marketed therapies generating significant revenue [2] Company Overview - Amicus Therapeutics focuses on developing and commercializing treatments for rare and orphan diseases, with a pipeline that includes therapies for genetic and metabolic disorders such as Fabry disease [3] - The company leverages precision science and patient-centric solutions to enhance long-term health outcomes for patients [3] Financial Performance - The combined revenue from Amicus's marketed therapies, Galafold and Pombiliti + Opfolda, reached $599 million over the past four quarters, indicating strong market performance [2]